Literature DB >> 1899854

Aberrant expression of HLA class-I antigens in Burkitt lymphoma cells.

M L Andersson1, N J Stam, G Klein, H L Ploegh, M G Masucci.   

Abstract

HLA class-I expression has been investigated by biochemical methods in 14 Burkitt lymphoma (BL) cell lines and the corresponding Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines (LCL) derived from the same individuals. Selective down-regulation of one or more HLA class-I specificities was demonstrated in 9 out of 14 BL lines. The defect was restricted to a single HLA-A allele in 3 of the lines (BL29, BL72, WW-I-BL). Four lines (BL28, BL37, BL41 and Jijoye M13) showed down-regulation of both HLA-A and -C alleles, and one (BL36) failed to express one HLA-C allele. Only one BL line (WW-2-BL) had lost one HLA-A and one HLA-B allele. The allele-specific defects were mainly detected in cell lines that had maintained the phenotypic characteristics of the original tumor. Expression of B-cell activation markers and the EBV-encoded nuclear antigen (EBNA)-2 correlated with up-regulation of the Cw4 allele in the P79 subline of the BL line Jijoye. Treatment with gamma-interferon (IFN) resulted in full or partial reversion of the HLA class-I defects in some of the cases but had no significant effect in others. This was not due to a cell-line-related unresponsiveness to IFN, nor did it reflect an allele-specific mode of regulation because the same allele could respond differently in different cell lines. The data suggest that defective expression of HLA class-I antigens, which appears to be more prevalent for alleles within the HLA-A and -C loci, is a common feature of BL cell lines. Different regulatory mechanisms appear to be involved.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1899854     DOI: 10.1002/ijc.2910470412

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  13 in total

1.  Recognition of the Epstein-Barr virus-encoded nuclear antigens EBNA-4 and EBNA-6 by HLA-A11-restricted cytotoxic T lymphocytes: implications for down-regulation of HLA-A11 in Burkitt lymphoma.

Authors:  R Gavioli; P O De Campos-Lima; M G Kurilla; E Kieff; G Klein; M G Masucci
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-01       Impact factor: 11.205

2.  Search for the critical characteristics of phenotypically different B cell lines, Burkitt lymphoma cells and lymphoblastoid cell lines, which determine differences in their functional interaction with allogeneic lymphocytes.

Authors:  J Avila-Cariño; S Torsteinsdottir; B Ehlin-Henriksson; M G Masucci; E Klein
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

3.  Epstein-Barr virus nuclear antigen 2 trans-activates the cellular antiapoptotic bfl-1 gene by a CBF1/RBPJ kappa-dependent pathway.

Authors:  Pamela M Pegman; Sinéad M Smith; Brendan N D'Souza; Sinéad T Loughran; Sabine Maier; Bettina Kempkes; Paul A Cahill; Matthew J Simmons; Céline Gélinas; Dermot Walls
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

Review 4.  Developing T-cell therapies for lymphoma without receptor engineering.

Authors:  Melanie Grant; Catherine M Bollard
Journal:  Blood Adv       Date:  2017-12-08

Review 5.  Modulation of major histocompatibility complex antigen expression by viral infection.

Authors:  C R Rinaldo
Journal:  Am J Pathol       Date:  1994-04       Impact factor: 4.307

Review 6.  Developing T-cell therapies for lymphoma without receptor engineering.

Authors:  Melanie Grant; Catherine M Bollard
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

7.  Application of isoelectric focusing for studies of major histocompatibility complex class I antigen expression on human carcinomas and sarcomas.

Authors:  P Wang; F Vánky; E Klein
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

8.  Repression of the proapoptotic cellular BIK/NBK gene by Epstein-Barr virus antagonizes transforming growth factor β1-induced B-cell apoptosis.

Authors:  Eva M Campion; Roya Hakimjavadi; Sinéad T Loughran; Susan Phelan; Sinéad M Smith; Brendan N D'Souza; Rosemary J Tierney; Andrew I Bell; Paul A Cahill; Dermot Walls
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

Review 9.  Selective mechanisms utilized by persistent and oncogenic viruses to interfere with antigen processing and presentation.

Authors:  R Ehrlich
Journal:  Immunol Res       Date:  1995       Impact factor: 2.829

10.  Bystander killing of cancer requires the cooperation of CD4(+) and CD8(+) T cells during the effector phase.

Authors:  Andrea Schietinger; Mary Philip; Rebecca B Liu; Karin Schreiber; Hans Schreiber
Journal:  J Exp Med       Date:  2010-10-04       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.